scholarly journals The effect of hyperbaric oxygen therapy on the pathophysiology of skin aging: a prospective clinical trial

Aging ◽  
2021 ◽  
Author(s):  
Yafit Hachmo ◽  
Amir Hadanny ◽  
Sonia Mendelovic ◽  
Pnina Hillman ◽  
Eyal Shapira ◽  
...  
PLoS ONE ◽  
2015 ◽  
Vol 10 (5) ◽  
pp. e0127012 ◽  
Author(s):  
Shai Efrati ◽  
Haim Golan ◽  
Yair Bechor ◽  
Yifat Faran ◽  
Shir Daphna-Tekoah ◽  
...  

2018 ◽  
Vol 54 (4) ◽  
pp. 188-194 ◽  
Author(s):  
Gemma L. Birnie ◽  
Darren R. Fry ◽  
Matthew P. Best

ABSTRACT This prospective clinical trial was designed to evaluate the safety of hyperbaric oxygen therapy (HBOT) in a population of cats and dogs with a variety of naturally occurring diseases. Seventy-eight dogs and twelve cats with various naturally occurring disease conditions, who had the potential to benefit from HBOT, were enrolled in the study. These patients were treated with HBOT in a monoplace hyperbaric oxygen chamber at 2 air pressure absolute for a treatment length of either 45 min or 60 min. There were 230 hyperbaric oxygen treatments performed during the study period. No major adverse effects were observed. There were 76 minor adverse effects recorded, which were not considered to be of clinical significance. Hyperbaric oxygen therapy was well tolerated and there were no major adverse effects recorded during treatment.


2020 ◽  
Vol 8 (1) ◽  
pp. e001590
Author(s):  
Aaron Drovandi ◽  
Malindu E Fernando ◽  
Tejas P Singh ◽  
Torres Woolley ◽  
Jonathan Golledge

IntroductionHyperbaric oxygen therapy (HBOT) has been suggested to improve healing of lower limb ulcers, though the quality of available evidence is weak to moderate. This study assessed the opinions and use of HBOT by specialists treating lower limb ulcers.Research design and methodsAccredited vascular surgeons and podiatrists in Australia and New Zealand were sent an online survey via their professional organizations. The survey asked about their use and opinions of HBOT in treating lower limb ischemic, neuropathic and venous ulcers. Data were summarized with descriptive statistics. Non-parametric tests were used to compare survey results obtained from vascular surgeons and podiatrists.Results61 vascular surgeons and 40 podiatrists completed the survey. Thirty-seven specialists used HBOT for treating lower limb ulcers, with the remainder indicating they did not feel there was a role for HBOT (n=25) or did not have access to HBOT (n=39). Less than 8% of specialists indicated that HBOT frequently or always had a role in treating ischemic, neuropathic or venous ulcers. Compared with podiatrists, vascular surgeons were significantly less likely to indicate HBOT had a treatment role for any ulcer type (p<0.001, p=0.004, and p<0.001, respectively), though significantly more likely to indicate they currently used HBOT for treating lower limb ulcers (p<0.001). Most specialists (n=76) believed that a large clinical trial is needed to determine the efficacy of HBOT in treating lower limb ulcers.ConclusionsVascular surgeons and podiatrists do not feel HBOT has a frequent role in treating lower limb ulcers, but do feel there needs to be a large clinical trial to test its value.


2014 ◽  
Vol 15 (2) ◽  
pp. 155-162 ◽  
Author(s):  
Farida El-baz ◽  
Reham M. Elhossiny ◽  
Yasser Abdel Azeem ◽  
Marianne Girgis

Sign in / Sign up

Export Citation Format

Share Document